Premium
Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer
Author(s) -
Emi Mitsuru,
Yoshimoto Masataka,
Sato Takaaki,
Matsumoto Satoshi,
Utada Yoshihito,
Ito Isao,
Minobe Kaori,
Iwase Takuji,
Katagiri Toyomasa,
Bando Kouichi,
Akiyama Futoshi,
Harada Yousuke,
Fukino Kouichi,
Sakamoto Goi,
Matsushima Mieko,
Iida Aritoshi,
Tada Takashi,
Saito Hiroko,
Miki Yoshio,
Kasumi Fujio,
Nakamura Yusuke
Publication year - 1999
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/(sici)1098-2264(199910)26:2<134::aid-gcc5>3.0.co;2-9
Subject(s) - breast cancer , oncology , medicine , cancer
Allelic losses of tumor suppressor genes (TSGs), or the chromosomal regions harboring them, in tumor DNA may become useful postoperative prognostic indicators. To examine whether specific allelic losses might correlate with postoperative survival in a 5‐year prospective follow‐up, we tested tumors from a cohort of 264 breast cancer patients for allelic losses of 18 microsatellite markers representing either a known TSG or a region where genetic alterations are frequent in breast tumors. Patients whose tumors had lost an allele at 1p34, 13q12, 17p13.3, or 17q21.1 had significantly higher risks of postoperative mortality than those whose tumors retained both alleles at those loci (at 1p34, a 5‐year mortality rate of 29% among patients with losses vs. 7% with retentions, P = 0.0008; at 13q12, 31% vs. 10%, P = 0.0062; at 17p13.3, 24% vs. 13%, P = 0.026; and at 17q21.1, 31% vs. 13%, P = 0.0047). Furthermore, combined losses at 13q12 and 17p13.3 increased the predicted postoperative mortality risks by a factor of 9.6 (5‐year mortality rate of 42% vs. 5% with retentions, P = 0.0001), and combined losses at 1p34 and 17p13.3 raised the predicted postoperative mortality risks by a factor of 8.6 (27% vs. 3%, P = 0.0064). We conclude that allelic losses at these loci can serve as negative prognostic indicators to guide postoperative management of patients. Genes Chromosomes Cancer 26:134–141, 1999. © 1999 Wiley‐Liss, Inc.